Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Pol? ATPase Inhibitor [Yahoo! Finance]
Repare Therapeutics Inc. - Common Shares (RPTX)
Company Research
Source: Yahoo! Finance
Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the first patient has been dosed in the Company's Phase 1 (POLAR) clinical trial evaluating RP-3467, a Pol? ATPase inhibitor, alone and in combination with the poly-ADP ribose polymerase (PARP) inhibitor, olaparib. RP-3467 is Repare's fourth clinical program. "RP-3467, our potential best-in-class Pol? ATPase inhibitor, has demonstrated highly compelling preclinical results, including complete and durable tumor regressions in combination with olaparib, the leading PARP inhibitor, with no additive toxicities. This combination is designed to meaningfully improve patient outcomes by mitigating PARP inhibitor resistance, a significant area of high unmet medical need," said Maria Koehler, MD, PhD, Executive Vice President and Chief Medical Officer of Repare. "In addition, Repare's previously reported data established the potential for RP-3467 to improve efficacy and limit
Show less
Read more
Impact Snapshot
Event Time:
RPTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RPTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RPTX alerts
High impacting Repare Therapeutics Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
RPTX
News
- Repare Therapeutics Inc. (NASDAQ: RPTX) had its "market perform" rating re-affirmed by analysts at Lifesci Capital.MarketBeat
- Repare Therapeutics eyes Phase III cancer study after Mythic trial success [Yahoo! Finance]Yahoo! Finance
- Repare Therapeutics Inc. (NASDAQ: RPTX) had its price target lowered by analysts at Stifel Nicolaus from $9.00 to $4.00. They now have a "buy" rating on the stock.MarketBeat
- Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical TrialBusiness Wire
- Repare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical Trial [Yahoo! Finance]Yahoo! Finance
RPTX
Earnings
- 2/28/24 - Miss
RPTX
Sec Filings
- 12/12/24 - Form 8-K
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- RPTX's page on the SEC website